Enveda Raised $311 Million for AI Drug Discovery
The company will use the Series E funding to advance its pipeline of oral drug candidates and scale its AI platform.
Updated on Sept. 23, 2026 in Biotech
Live Poll
Do you believe AI-driven drug development will make medical treatments more affordable and effective?
Enveda has secured $311 million in a Series E funding round, bringing its total lifetime capital raised to $845 million. The company is currently utilizing its AI-native discovery platform to move three oral drug candidates through clinical trials.
Why it matters
This financing enables Enveda to transition its existing clinical programs into later-stage development while accelerating the generation of new first-in-class therapies. The capital deployment focuses on scaling the company's proprietary discovery engine to support an expanding portfolio.
Enveda has generated 17 total development candidates using its PRISM AI platform, which identifies biologically active molecules from nature. The firm currently has three oral candidates in clinical trials, including two that reported positive early results in 2026.
The players
Enveda
A biotechnology firm developing an AI-native drug discovery platform focused on identifying biologically active molecules in nature.
Catalio Capital Management
A life sciences investment firm that led the Series E financing round for Enveda.
The details
Enveda utilizes a platform called PRISM—an AI-native system that maps the structural and biological properties of molecules found in nature—to accelerate the drug discovery process. By analyzing these natural compounds, the platform identifies candidates that can be developed into clinical treatments. The firm's active clinical pipeline includes ENV-294 for atopic dermatitis and ENV-308, which targets metabolic health to prevent weight gain following GLP-1 therapy.
Timeline
2026: Two drug candidates reported positive early clinical results.
The Tech Race
The firm is positioning its candidate ENV-308 to address metabolic health challenges specifically following GLP-1 therapy, identifying a new niche in the crowded weight management field. This move reflects a broader industry trend of using AI platforms to find specialized applications for existing drug classes.
The company plans to transition its current clinical programs into later-stage trials, which is a necessary step before these oral treatments can reach potential commercial approval. Patients and clinicians should monitor future clinical trial updates to determine when these candidates might reach regulatory review phases.
The takeaway
Enveda is attempting to prove that AI-driven natural product discovery can successfully deliver first-in-class oral medicines. Watch for the progression of clinical results for ENV-294 and ENV-308 as key indicators of the platform's long-term efficacy.
Further reading
For more on the latest trends in the industry, visit Biotech.
Live Poll
Do you believe AI-driven drug development will make medical treatments more affordable and effective?
